In summary, targeting the PI3K/Akt/mTOR pathway to subvert resistance to ET in breast cancer is now proven to be of clinical benefit with everolimus and alpelisib already used routinely in clinical practice. This evidence concerns the gene PIK3CA and breast carcinoma.